MX2018003376A - Prediccion de la respuesta clinica a antagonistas de il23 mediante el uso de biomarcadores de la via de il23. - Google Patents
Prediccion de la respuesta clinica a antagonistas de il23 mediante el uso de biomarcadores de la via de il23.Info
- Publication number
- MX2018003376A MX2018003376A MX2018003376A MX2018003376A MX2018003376A MX 2018003376 A MX2018003376 A MX 2018003376A MX 2018003376 A MX2018003376 A MX 2018003376A MX 2018003376 A MX2018003376 A MX 2018003376A MX 2018003376 A MX2018003376 A MX 2018003376A
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- treatment
- therapeutic agent
- pathway
- biomarkers
- Prior art date
Links
- 239000000090 biomarker Substances 0.000 title abstract 3
- 230000037361 pathway Effects 0.000 title abstract 3
- 239000005557 antagonist Substances 0.000 title abstract 2
- 102000013264 Interleukin-23 Human genes 0.000 abstract 6
- 108010065637 Interleukin-23 Proteins 0.000 abstract 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
- 201000010099 disease Diseases 0.000 abstract 4
- 230000001404 mediated effect Effects 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 3
- 229940124597 therapeutic agent Drugs 0.000 abstract 3
- 208000011231 Crohn disease Diseases 0.000 abstract 2
- 101001010626 Homo sapiens Interleukin-22 Proteins 0.000 abstract 1
- 101001023833 Homo sapiens Neutrophil gelatinase-associated lipocalin Proteins 0.000 abstract 1
- 102100030703 Interleukin-22 Human genes 0.000 abstract 1
- 102100035405 Neutrophil gelatinase-associated lipocalin Human genes 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562220062P | 2015-09-17 | 2015-09-17 | |
| PCT/US2016/052060 WO2017049035A1 (en) | 2015-09-17 | 2016-09-16 | Prediction of clinical response to il23-antagonists using il23 pathway biomarkers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018003376A true MX2018003376A (es) | 2018-08-15 |
Family
ID=58289919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018003376A MX2018003376A (es) | 2015-09-17 | 2016-09-16 | Prediccion de la respuesta clinica a antagonistas de il23 mediante el uso de biomarcadores de la via de il23. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11016099B2 (enExample) |
| EP (1) | EP3349854A4 (enExample) |
| JP (3) | JP6909208B2 (enExample) |
| KR (1) | KR20180063127A (enExample) |
| CN (2) | CN108290058B (enExample) |
| AU (1) | AU2016323579A1 (enExample) |
| BR (1) | BR112018005175A2 (enExample) |
| CA (1) | CA2998349A1 (enExample) |
| HK (1) | HK1258292A1 (enExample) |
| IL (1) | IL257969A (enExample) |
| MX (1) | MX2018003376A (enExample) |
| RU (1) | RU2018113694A (enExample) |
| WO (1) | WO2017049035A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| US10370718B2 (en) | 2014-09-29 | 2019-08-06 | Immusant, Inc. | Use of HLA genetic status to assess or select treatment of celiac disease |
| CA2998349A1 (en) | 2015-09-17 | 2017-03-23 | Amgen Inc. | Prediction of clinical response to il23-antagonists using il23 pathway biomarkers |
| TW201922780A (zh) * | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法 |
| WO2019113037A1 (en) * | 2017-12-04 | 2019-06-13 | Immusant, Inc. | Measurement of ccl20 after gluten exposure |
| KR20200097286A (ko) * | 2017-12-07 | 2020-08-18 | 암젠 인크 | 로미플로스팀을 사용한 특발성 혈소판 감소 자반병(itp)의 치료 방법 |
| US20190269757A1 (en) | 2018-03-05 | 2019-09-05 | Janssen Biotech, Inc. | Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody |
| EP3793521A4 (en) | 2018-05-18 | 2022-02-23 | Janssen Biotech, Inc. | SAFE AND EFFECTIVE METHOD OF TREATING LUPUS WITH AN ANTI-IL12/IL23 ANTIBODY |
| EP3824295A4 (en) * | 2018-07-18 | 2022-04-27 | Janssen Biotech, Inc. | PREDICTORS WITH DELAYED ACTION AFTER TREATMENT WITH ANTI-IL23 SPECIFIC ANTIBODIES |
| KR20210064315A (ko) * | 2018-09-24 | 2021-06-02 | 얀센 바이오테크 인코포레이티드 | 항-il12/il23 항체로 궤양성 결장염을 치료하는 안전하고 효과적인 방법 |
| WO2020104705A2 (en) * | 2018-11-23 | 2020-05-28 | Katholieke Universiteit Leuven | Predicting a treatment response in inflammatory bowel disease |
| CN109337974B (zh) * | 2018-12-14 | 2022-01-25 | 北京蛋白质组研究中心 | 一种检测银屑病的诊断标志物的试剂及其应用 |
| EP3897722A4 (en) * | 2018-12-18 | 2022-09-14 | Janssen Biotech, Inc. | SAFE AND EFFECTIVE METHOD OF TREATMENT OF LUPUS WITH ANTI-IL12/IL23 ANTIBODIES |
| CN113853385A (zh) * | 2019-03-18 | 2021-12-28 | 詹森生物科技公司 | 用抗il12/il23抗体治疗儿科受试者的银屑病的方法 |
| CN113710316A (zh) * | 2019-03-26 | 2021-11-26 | 阿斯特捷利康合作创业有限责任公司 | 适合于il23拮抗剂疗法的患者群体 |
| JP7778567B2 (ja) * | 2019-04-17 | 2025-12-02 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | α４β７阻害薬及びＩＬ－２３阻害薬の併用療法 |
| BR112021023295A2 (pt) | 2019-05-23 | 2022-02-08 | Janssen Biotech Inc | Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa |
| CN114641493A (zh) * | 2019-08-21 | 2022-06-17 | 阿斯特捷利康合作创业有限责任公司 | 使用布雷库单抗治疗克罗恩病 |
| EP4424381A3 (en) * | 2019-10-18 | 2024-11-13 | Janssen Biotech, Inc. | Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody |
| EP4067372A4 (en) * | 2019-11-29 | 2023-11-08 | Toyobo Co., Ltd. | RECOMBINANT C-REACTIVE PROTEIN |
| US11396541B2 (en) | 2019-12-20 | 2022-07-26 | Novarock Biotherapeutics, Ltd. | Anti-interleukin-23 P19 antibodies and methods of use thereof |
| JP2023514567A (ja) * | 2020-02-14 | 2023-04-06 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｉｌ１２／ｉｌ２３抗体で潰瘍性大腸炎を治療する安全かつ有効な方法 |
| CN111424086A (zh) * | 2020-03-19 | 2020-07-17 | 上海交通大学 | 用于胃癌诊断及预后评估的生物标记物及应用和检测试剂盒 |
| JP2023528265A (ja) | 2020-05-21 | 2023-07-04 | ヤンセン バイオテツク，インコーポレーテツド | Ｉｌ－２３に対する抗体及びｔｎｆアルファに対する抗体の組み合わせ療法を用いた炎症性腸疾患の治療方法 |
| CA3196112A1 (en) * | 2020-10-23 | 2022-04-28 | Hq Han | Bifunctional antagonists of activin and tumor necrosis factor-alpha and uses thereof |
| AU2021385427A1 (en) | 2020-11-30 | 2023-06-29 | Mindera Corporation | Microneedle devices and methods, and skin condition assays |
| US20220373539A1 (en) * | 2021-05-24 | 2022-11-24 | Amgen Inc. | Prediction of clinical response to il23-antagonists using il23 pathway biomarkers |
| WO2025170982A2 (en) | 2024-02-06 | 2025-08-14 | Paragon Therapeutics, Inc. | Il-23 antibody compositions and methods of use |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8318754D0 (en) | 1983-07-11 | 1983-08-10 | Fagerhol M K F | Human proteins anti-sera test kits |
| US5455160A (en) | 1993-05-27 | 1995-10-03 | Fagerhol; Magne K. | Diagnostic test and kit for disease or disorders in the digestive system |
| DK0937259T3 (da) | 1996-11-01 | 2005-01-31 | Magne K Fagerhol | Fremgangsmåde til ekstraktion af proteiner |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| CO4810232A1 (es) | 1997-07-25 | 1999-06-30 | Schering Corp | Citoquinas de mamiferos y sus secuencias codificadoras |
| US7226591B2 (en) | 2000-05-22 | 2007-06-05 | Genentech, Inc. | Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders |
| DK1311679T3 (da) | 2000-08-24 | 2009-02-23 | Genentech Inc | Fremgangsmåde til inhibering af IL-22-induceret PAP1 |
| AU2005220910A1 (en) | 2004-03-05 | 2005-09-22 | Archemix Corp. | Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics |
| WO2005107793A2 (en) | 2004-05-06 | 2005-11-17 | The Trustees Of Columbia University | Ngal for reduction and amelioration of ischemic and nephrotoxic injuries |
| KR100681763B1 (ko) | 2005-02-28 | 2007-02-15 | 재단법인 목암생명공학연구소 | 인간 리포칼린 2를 유효성분으로 포함하는 암 전이 억제용약학적 조성물, 이를 이용한 암 전이 억제 방법 |
| EP3501537A1 (en) | 2005-06-30 | 2019-06-26 | Janssen Biotech, Inc. | Anti-il23 antibodies, compositions, methods and uses |
| EP1937721B1 (en) | 2005-08-25 | 2010-07-28 | Eli Lilly And Company | Anti-il-23 antibodies |
| HUE032131T2 (en) | 2005-08-31 | 2017-09-28 | Merck Sharp & Dohme | Constructed anti-IL-23 antibodies |
| BRPI0615297A2 (pt) | 2005-09-01 | 2011-05-17 | Schering Corp | antagonistas de il-23 e de il-17 para tratar doença inflamatória ocular auto-imune e seus usos |
| DK2548577T3 (en) | 2005-12-29 | 2017-03-13 | Janssen Biotech Inc | HUMAN ANTI-IL-23 ANTIBODIES, COMPOSITIONS, PROCEDURES AND APPLICATIONS |
| US20070203216A1 (en) | 2006-02-14 | 2007-08-30 | Bjarke Ebert | Method of treating inflammatory diseases |
| WO2007098065A2 (en) | 2006-02-17 | 2007-08-30 | The United States Of America As Represented By The Department Of Veterans Affairs | Human sodium channel isoforms |
| JP2009540018A (ja) | 2006-06-13 | 2009-11-19 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法 |
| AU2007261019A1 (en) | 2006-06-19 | 2007-12-27 | Wyeth | Methods of modulating IL-22 and IL-17 |
| GB0613470D0 (en) | 2006-07-06 | 2006-08-16 | Ares Trading Sa | Protein |
| WO2008028044A2 (en) | 2006-08-30 | 2008-03-06 | Centocor, Inc. | Markers and methods for assessing and treating ulcerative colitis and related disorders using 66 gene panel |
| ATE554791T1 (de) | 2007-02-23 | 2012-05-15 | Schering Corp | Gentechnisch hergestellte anti-il-23p19- antikörper |
| CN103396489A (zh) | 2007-02-23 | 2013-11-20 | 默沙东公司 | 工程改造的抗IL-23p19抗体 |
| AR068723A1 (es) | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
| US20090269777A1 (en) | 2007-10-19 | 2009-10-29 | Abbott Laboratories | Immunoassays and kits for the detection of ngal |
| WO2009052400A1 (en) | 2007-10-19 | 2009-04-23 | Abbott Laboratories | Antibodies that bind to mammalian ngal and uses thereof |
| US20090123946A1 (en) | 2007-10-19 | 2009-05-14 | Abbott Laboratories | Immunoassays and kits for the detection of ngal |
| EP2215481B2 (en) | 2007-11-15 | 2017-01-18 | Bioporto Diagnostics A/S | Diagnostic use of individual molecular forms of a biomarker |
| WO2009082624A2 (en) | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonists of il-17a, il-17f, and il-23 and methods of using the same |
| WO2009114756A2 (en) | 2008-03-14 | 2009-09-17 | Exagen Diagnostics, Inc. | Biomarkers for inflammatory bowel disease and irritable bowel syndrome |
| US20100227775A1 (en) | 2008-04-16 | 2010-09-09 | Abbott Laboratories | Immunoassays and kits for the detection of ngal |
| CA2734919C (en) | 2008-08-27 | 2016-08-16 | Schering Corporation | Lyophilized formulations of engineered anti-il-23p19 antibodies |
| GB2464183A (en) | 2008-09-19 | 2010-04-14 | Singulex Inc | Sandwich assay |
| EP2347256A4 (en) | 2008-10-09 | 2012-02-08 | Alfagene Bioscience Inc | USE AND IDENTIFY BIOMARKERS FOR STOMACH DISEASES |
| US20100105150A1 (en) | 2008-10-24 | 2010-04-29 | Abbott Laboratories | Isolated human autoantibodies to neutrophil gelatinase-associated lipocalin (ngal) and methods and kits for the detection of human autoantibodies to ngal |
| US20110212104A1 (en) | 2008-11-03 | 2011-09-01 | Schering Corporation | Inflammatory bowel disease biomarkers and related methods of treatment |
| US20120128689A1 (en) | 2009-04-01 | 2012-05-24 | Glaxo Group Limited | Anti-il-23 immunoglobulins |
| WO2010129964A1 (en) | 2009-05-08 | 2010-11-11 | The Board Of Trustees Of The University Of Illinois | Drug targets for prevention of arrhythmia in heart disease |
| WO2010142534A1 (en) | 2009-05-27 | 2010-12-16 | Ablynx Nv | Biparatopic protein constructs directed against il-23 |
| AU2010266028B2 (en) | 2009-06-25 | 2015-04-30 | Société des Produits Nestlé S.A. | Methods for diagnosing irritable bowel syndrome |
| WO2011005779A2 (en) | 2009-07-07 | 2011-01-13 | University Of Southern California | Biomarkers for the early detection of autoimmune diseases |
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| CA2781654A1 (en) | 2009-11-25 | 2011-06-03 | Hua Gong | Novel genomic biomarkers for irritable bowel syndrome diagnosis |
| EA031209B9 (ru) | 2010-01-15 | 2021-11-19 | Кирин-Эмджен, Инк. | Фармацевтический состав антитела для лечения воспалительного заболевания и способы его применения |
| JP5972871B2 (ja) | 2010-07-20 | 2016-08-17 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | 抗ｉｌ−２３ヘテロ二量体特異的抗体 |
| US8541180B1 (en) | 2010-10-11 | 2013-09-24 | Genova Diagnostics, Inc. | Compositions and methods for assessing gastrointestinal health |
| PL2635601T3 (pl) * | 2010-11-04 | 2017-02-28 | Boehringer Ingelheim International Gmbh | Przeciwciała anty-il-23 |
| CA2824419A1 (en) | 2011-01-06 | 2012-07-12 | The United States Government As Represented By The Department Of Veteran S Affairs | Scn5a splice variants for use in methods relating to sudden cardiac death and need for implanted cardiac defibrillators |
| GB201100282D0 (en) | 2011-01-07 | 2011-02-23 | Ucb Pharma Sa | Biological methods |
| US10208349B2 (en) | 2011-01-07 | 2019-02-19 | Ucb Biopharma Sprl | Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy |
| WO2012115885A1 (en) | 2011-02-22 | 2012-08-30 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers |
| CA3290895A1 (en) | 2011-04-29 | 2025-11-29 | Lung Cancer Proteomics Llc | Methods of identification and diagnosis of lung diseases using classification systems and kits thereof |
| WO2012158831A1 (en) | 2011-05-16 | 2012-11-22 | Prometheus Laboratories Inc. | Performance of a biomarker panel for irritable bowel syndrome |
| NO20110895A1 (no) | 2011-06-21 | 2012-12-24 | Magne Fagerhol | Kompetitive S100A9 immunoanalyser |
| NO336551B1 (no) | 2011-06-21 | 2015-09-28 | Magne Fagerhol | Forbedret ELISA for kalprotektin i fekalprøve eller gastrointestinaltraktsprøve |
| CN103874770A (zh) | 2011-08-08 | 2014-06-18 | 卡里斯生命科学卢森堡控股有限责任公司 | 生物标志物组合物和方法 |
| JP2015505564A (ja) | 2012-02-03 | 2015-02-23 | テバ ファーマシューティカル インダストリーズ リミティド | 第一選択の抗ＴＮＥα療法に失敗したクローン病患者を治療するためのラキニモドの使用 |
| WO2013132347A2 (en) | 2012-03-06 | 2013-09-12 | Calpro As | Improved elisa immunoassay for calprotectin |
| WO2013132338A2 (en) | 2012-03-06 | 2013-09-12 | Calpro As | Competitive immunoassay for calprotectin |
| WO2013152114A1 (en) | 2012-04-03 | 2013-10-10 | The Regents Of The University Of Michigan | Biomarker associated with irritable bowel syndrome and crohn's disease |
| RU2015112024A (ru) | 2012-10-05 | 2016-11-27 | Дженентек, Инк. | Способы диагностики и лечения воспалительного заболевания кишечника |
| CN119709943A (zh) | 2014-05-15 | 2025-03-28 | 中尺度技术有限责任公司 | 改进的测定方法 |
| US20160000936A1 (en) | 2014-06-10 | 2016-01-07 | Abbvie Inc. | Biomarkers for inflammatory disease and methods of using same |
| EP3708679A1 (en) | 2014-07-24 | 2020-09-16 | Boehringer Ingelheim International GmbH | Biomarkers useful in the treatment of il-23a related diseases |
| CA2998349A1 (en) | 2015-09-17 | 2017-03-23 | Amgen Inc. | Prediction of clinical response to il23-antagonists using il23 pathway biomarkers |
| GB201521357D0 (en) | 2015-12-03 | 2016-01-20 | Univ Liverpool | Methods for predicting response to anti-TNF therapy |
| RU2018124603A (ru) | 2015-12-22 | 2020-01-24 | Эмджен Инк. | Ccl20 как прогностический фактор клинического ответа на антагонисты ил-23 |
| US20200064357A1 (en) | 2016-11-09 | 2020-02-27 | Protagonist Therapeutics, Inc. | Methods for determining and monitoring gastrointestinal inflammation |
| WO2018119626A1 (zh) | 2016-12-27 | 2018-07-05 | 菲鹏生物股份有限公司 | 中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒 |
-
2016
- 2016-09-16 CA CA2998349A patent/CA2998349A1/en not_active Abandoned
- 2016-09-16 WO PCT/US2016/052060 patent/WO2017049035A1/en not_active Ceased
- 2016-09-16 BR BR112018005175A patent/BR112018005175A2/pt not_active Application Discontinuation
- 2016-09-16 AU AU2016323579A patent/AU2016323579A1/en not_active Abandoned
- 2016-09-16 CN CN201680066986.XA patent/CN108290058B/zh not_active Expired - Fee Related
- 2016-09-16 HK HK19100656.4A patent/HK1258292A1/zh unknown
- 2016-09-16 MX MX2018003376A patent/MX2018003376A/es unknown
- 2016-09-16 US US15/759,330 patent/US11016099B2/en active Active
- 2016-09-16 JP JP2018514414A patent/JP6909208B2/ja not_active Expired - Fee Related
- 2016-09-16 CN CN202310427386.3A patent/CN116672446A/zh active Pending
- 2016-09-16 EP EP16847353.6A patent/EP3349854A4/en not_active Withdrawn
- 2016-09-16 RU RU2018113694A patent/RU2018113694A/ru not_active Application Discontinuation
- 2016-09-16 KR KR1020187010308A patent/KR20180063127A/ko not_active Withdrawn
-
2018
- 2018-03-08 IL IL257969A patent/IL257969A/en unknown
-
2021
- 2021-07-02 JP JP2021110695A patent/JP7153775B2/ja active Active
-
2022
- 2022-10-03 JP JP2022159196A patent/JP2023002583A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023002583A (ja) | 2023-01-10 |
| JP7153775B2 (ja) | 2022-10-14 |
| KR20180063127A (ko) | 2018-06-11 |
| US20180252728A1 (en) | 2018-09-06 |
| RU2018113694A3 (enExample) | 2020-01-31 |
| JP2018535394A (ja) | 2018-11-29 |
| RU2018113694A (ru) | 2019-10-17 |
| JP6909208B2 (ja) | 2021-07-28 |
| HK1258292A1 (zh) | 2019-11-08 |
| JP2021170017A (ja) | 2021-10-28 |
| BR112018005175A2 (pt) | 2018-10-16 |
| EP3349854A4 (en) | 2019-04-03 |
| IL257969A (en) | 2018-05-31 |
| CN116672446A (zh) | 2023-09-01 |
| CA2998349A1 (en) | 2017-03-23 |
| US11016099B2 (en) | 2021-05-25 |
| CN108290058A (zh) | 2018-07-17 |
| WO2017049035A1 (en) | 2017-03-23 |
| EP3349854A1 (en) | 2018-07-25 |
| CN108290058B (zh) | 2023-05-16 |
| AU2016323579A1 (en) | 2018-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018003376A (es) | Prediccion de la respuesta clinica a antagonistas de il23 mediante el uso de biomarcadores de la via de il23. | |
| MX2018007589A (es) | Ccl20 como indicador de respuesta clinica a antagonistas de il23. | |
| MX2018004170A (es) | Biomarcadores relacionados con enfermedades mediadas por interleucina-33 (il-33) y usos de los mismos. | |
| ZA201803207B (en) | MR-proADM AS MARKER FOR THE EXTRACELLULAR VOLUME STATUS OF A SUBJECT | |
| BR112014011127A2 (pt) | métodos para tratar, diagnosticar e monitorar doença de alzheimer | |
| UA115439C2 (uk) | Гуманізоване антитіло, яке розпізнає альфа-синуклеїн | |
| Deangelis et al. | Diagnosis of multiple sclerosis | |
| EA201291040A1 (ru) | Использование скорости увеличения желудочков при лечении болезни альцгеймера внутривенным иммуноглобулином | |
| Chua et al. | Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer | |
| BR112019005274A2 (pt) | anticorpo isolado ou fragmento do mesmo, composição, célula isolada, e, métodos para tratar uma doença ou condição inflamatória ou autoimune, para tratar um câncer, para reduzir ou aliviar dor e para detectar expressão de gm-csf em uma amostra. | |
| JP2015503106A5 (enExample) | ||
| SG11201901435UA (en) | Monoclonal antibody against melk and utilization thereof | |
| Tekeoğlu et al. | AB0247 Mean Platelet Volume: A Controversial Marker of Disease Activity in Rheumatoid Arthritis | |
| Han et al. | Estrogen promotes the angiogenesis and osteogenesis of bone marrow stromal cells via regulating ESR1/RUNX2 axis | |
| Navarro et al. | 299 Differential abundance of mirnas circulating in peripheral blood of patients with class iv lupus nephritis | |
| UA106257U (uk) | Спосіб прогнозування зрощення перелому | |
| Nakaya et al. | Transplant-Ineligible Symptomatic but Indolent Multiple Myeloma Shows Better Prognosis with Conventional Agents | |
| UA106228U (uk) | Спосіб прогнозування зрощення перелому | |
| Miller et al. | C80-A EVERYTHING YOU NEED TO KNOW ABOUT BRONCHOPULMONARY DYSPLASIA, CYSTIC FIBROSIS AND DIFFUSE PARENCHYMAL LUNG DISEASES: Vitamin D Binding Protein And Alpha-1-Acid Glycoprotein Levels In Serum Are Associated With Lymphangioleiomyomatosis | |
| UA106723U (uk) | Спосіб прогнозування зрощення перелому | |
| UA106229U (uk) | Спосіб прогнозування зрощення перелому | |
| UA106280U (uk) | Спосіб прогнозування зрощення перелому | |
| Korol et al. | PREDICTICAL VALUE OF DETERMINING THE OXIDATIVSTRESS INDEX IN BLOOD SERUM OF PATIENTS WITH PYELONEPHRITIS | |
| UA106297U (uk) | Спосіб прогнозування зрощення перелому | |
| UA94364U (uk) | Спосіб прогнозування незрощення перелому |